Mubadala’s KELIX bio acquires DiabTec
KELIX bio, wholly owned by Mubadala, has completed the acquisition of DiabTec, a subsidiary of Julphar.
** For the best experience, download the free Africa Private Equity News app Android | iOS **
KELIX bio, wholly owned by Mubadala Investment Company, an Abu Dhabi sovereign investor, has completed the acquisition of DiabTec, a subsidiary of Julphar. This acquisition strengthens Mubadala's portfolio of biologicals, establishes its role in biomanufacturing across the Middle East and North Africa (MENA) region, and supports its efforts to advance the UAE's life sciences sector through local manufacturing.
Africa-focused private equity firm Development Partners International (DPI) announced the close of its exit from KELIX bio to Mubadala in October 2024. DPI created KELIX bio alongside management and co-investors British International Investment and EBRD in 2020.
DiabTec's facility includes 20,000-litre drug substance reactors and a separate cartridge fill-finish facility for drug products. The facility is currently the only one of its kind in the GCC.
Stay ahead in Africa's private equity and venture capital sector with Africa Private Equity News’ monthly Dealmaker’s Log – a database of reported investment deals, exits, and fundraising closes. Subscribe here